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local control (LC), regional control (RC) and metastasis-free survival 
(MFS).  
A strong correlation between total lymph node tumour volume and N-
stage was found (Rs=0.93, P<0.01). MFS was worse with involvement 
of the lower neck levels (Rs=0.345, P<0.01). Patients with larger total 
lymph node tumour volumes had poorer RC and MFS rates, 
independent of treatment regimen. For total lymph node volumes up 
to 3.5 cm3, MFS can be improved by ARCON (P<0.01). 
Conclusions: The strong prognostic value of T-stage and primary 
tumour volume, observed in retrospective analyses was not confirmed 
in patients treated in a prospective randomised trial with accelerated 
radiotherapy with or without carbogen breathing and nicotinamide. 
Results of this study indicate that (biological) factors other than 
primary tumour volume and T-stage are needed to select patients 
with laryngeal cancer for treatment intensification.  
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Purpose/Objective: Radiotherapy combined with targeting of the 
epidermal growth factor receptor (EGFR) is considered to be a 
promising new tool to increase tumor control. However, the data 
available so far, indicate that probably only a subgroup of patients 
may actually benefit from this new treatment. In order to identify 
these patients the mechanisms of EGFR targeting has to be known. We 
asked whether cell cycle effects as caused by EGFR targeting may play 
a critical role when combined with irradiation and whether 
biomarkers can be established for this interaction. 
Materials and Methods: Study was performed with cell lines differing 
in p53 status (A549, H1299, H460, H3122, HCT116, FaDu) as well as in 
A549 grown as xenografts. Cell cycle analysis was measured via 
FACScan and kinetics of G1 population was followed using colcemid 
assay. Protein expression was determined via Western, p21 was 
knocked down via siRNA; cell survival by colony assay, for xenograft 
model tumor control probability was determined after conventional 
fractionation. 
Results: Targeting of EGFR alone by tyrosine kinase inhibitors 
(Erlotinib and BIBX1382BS) was able to induce a strongly pronounced 
accumulation of cells in G1. But this effect was mostly transient. In 
combination with X-irradiation both TK inhibitors were found to 
enhance the radiation-induced permanent G1 arrest to a great extant. 
This effect, however, only occurred in cells with intact p53/p21 
signaling. No such an effect was seen in tumor cells mutated in p53 or 
deleted in p21 or when p21 was knocked down via siRNA. For tumor 
cell lines showing this increase in permanent G1 arrest, TK inhibitors 
were always found to result in a moderately enhanced cellular 
radiosensitivity and vice versa. In a xenograft model, blockage of 
EGFR was also found to result in a trend towards higher local control. 
Conclusions: Overall these data suggest that both in vitro as well as 
in vivo EGFR inhibition may lead to a moderately increased 
radiosensitivity but only when p53/p21 signaling is intact. In order to 
increase these effects on tumors, radiation and EGFR targeting need 
to be combined with agents specifically affecting the permanent G1 
arrest.  
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Purpose/Objective: Treatment of larger and more centrally located 
lung tumors with SABR results in high local control, but higher rates of 
radiation pneumonitis (RP) have been reported. We studied predictors 
of RP in high-risk patients treated with SABR, to optimize treatment 
planning objectives. 
Materials and Methods: A review was performed of 79 SABR patients 
at high risk for RP, due to either a PTV>100cc (n=69) or prior 
pneumonectomy or bi-lobectomy (n=13). All were treated using 
RapidArc with risk-adapted fractionation schedules. Volume of the 
total lung(TL), ipsi-(IL) and contralateral lung (CL) receiving 5Gy (V5) 
to 50Gy (V50) with 5Gy increments were calculated after converted 
dose to biologically equivalent doses (α/β 3). These factors, mean 
lung dose (MLD) and clinical parameters were included in univariable 
and multivariable logistic regression to identify predictors of CTCAE 
v4.03 grade ≥3 RP. Concordance-statistics (C-statistic) were used to 
quantify the degree of association of the factors with high grade RP. 
Results: Median follow-up of patients alive was 12.6 months (2.5-
32.5). Median PTV was 150cc (13-411cc). Grade≥3 RP was observed in 
8 patients (10.1%), at a median time to onset of 6.1 months. In 
univariable analysis, CL-MLD, CL-V5-15,TL-MLD, TL-V5 and V10 as well 
as the ITV volume were all related with RP (all p-values <0.05). 
Multivariable analysis showed contralateral MLD (p=.007) and ITV 
(p=.063) to best predict grade ≥3 RP, and the model achieved 
excellent discrimination with a C-statistic of 0.87. The highest risk for 
RP was found if the contralateral MLD was ≥ 3.6Gy (for 3 out of 8 
patients) or if ITV size was ≥ 145cc (2 out of 7 patients). Lowest risk (1 
case out of 54) was found for patients outside these two groups. 
Conclusions: The contralateral MLD and ITV strongly correlated with 
risk of Grade≥3 pneumonitis after SABR. New strategies are needed to 
minimize this risk.  
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Purpose/Objective: Traditionally patients with contralateral hilar or 
supraclavicular lymph nodes are often denied curative treatment for 
stage III small cell lung cancer (SCLC). We hypothesized that the 
prognostic impact of these lymph nodes is less pronounced in PET-
staged SCLC patients due to more accurate staging.  
Materials and Methods: Analysis of 111 patients in our prospective 
database with stage I-III SCLC referred for concurrent chemo-
radiotherapy. All patients received a PET-scan as part of their staging 
work-up. Standard treatment was 45 Gy in 1.5 Gy fractions twice daily 
concurrently with carboplatin-etoposide, followed by prophylactic 
cranial irradiation (PCI) in case of non-progression. Only PET-positive 
or pathologically proven lymph nodes were included in the Gross 
Tumor Volume (GTV). Survival was calculated from pathologic 
diagnosis (Kaplan-Meier method). 
Results: Out of 111 patients, 10 (9%) had contralateral hilar and 29 
(26%) had supraclavicular lymph nodes. Median overall survival for the 
entire cohort was 20 months (95% CI 17.8-22.1 months), 2-year 
survival 39%. In univariate analysis neither having supraclavicular 
nodes (p= 0.675) or contralateral hilar nodes (p=0.536) significantly 
impacted survival. Median survival was 19 months (95% CI 16-21.9 
months) for stage III patients with contralateral hilar and/or 
supraclavicular lymph nodes and 21 months (95% CI 16-25.9 months) 
for other patients with stage I-III disease. 
In a multivariate Cox regression analysis including WHO-PS, age, 
gender, LDH, PCI, time between start of any treatment and the end of 
radiotherapy (SER), GTV, stage and having supraclavicular or 
contralateral hilar lymph nodes only WHO-PS (p=0.011), GTV (p=0.025) 
and delivery of PCI (p<0.001) reached significance. Patients with 
supraclavicular (p=0.997) or contralateral hilar lymph nodes (p=0.749) 
did not have a significantly worse prognosis. 
Conclusions: In stage I-III SCLC staged with PET and treated with 
modern concurrent chemo-radiation, the presence of supraclavicular 
or contralateral hilar lymph nodes does not have a significant impact 
on overall survival. These patients should therefore be offered 
treatment with curative intent. 
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Purpose/Objective: During the course of their disease, 30-60% of lung 
cancer patients (pts) develop brain metastasis (BM). Despite local 
and/or systemic treatment survival is dismal. Depending on the 
Recursive Partitioning Analysis (RPA) class median survival is 7 months 
for class 1 and 3 months for class 3. In 2011 the Dutch national 
guideline on BM was revised, advising to actively treat pts with more 
than 3 BM both in RPA class 1 and the majority of pts in class 2 with 
Whole Brain Radiotherapy (WBRT). With lacking evidence of benefit, 
pts in RPA class 3 should be strictly treated palliatively. In this 
retrospective study in a large lung cancer patient cohort we evaluate 
the guideline’s use in daily practice. 
Materials and Methods: Data of all lung cancer pts who underwent 
WBRT for BM referred from one of three collaborating hospitals in the 
South of the Netherlands between March 2004 and July 2012 were 
retrospectively analyzed. Details on performance score (according to 
WHO/Karnofsky(KPS)), age, locally controlled disease, extracranial 
metastasis, time from diagnosis of lung cancer to development of BM, 
histology and survival after diagnosis of BM were collected. The RPA 
class was determined using the first four items. 
Results: 292 WBRT pts had NSCLC. Average age (range) was 62.6 years 
(40.5-83.5) , 59.2% was male, 252 (68.3%) had a KPS of ≥ 70. In 215 
(73.6%) pts the primary tumor was not controlled, 116 (39.7%) had 
extra-cranial metastasis, 93 (31.9%) had BM at primary diagnosis. 96 
WBRT pts had SCLC, average age was 62.1 years (44.7-83.5) , 64.0% 
was male, 86 (89.6%) had a KPS of ≥ 70. In 71 (74.0%) pts the primary 
tumor was not controlled, 37 (38.5%) had extracranial metastasis and 
24 (25.0%) had BM at primary diagnosis.  
For NSCLC, 45 (15.4%) of 292 pts were classified as RPA 1, 210 (71.9%) 
as RPA 2, and 37 (12.7%) as RPA 3. For SCLC this was 7 (7.3%), 75 
(78.1%), and 14 (14.6%), respectively. Before the revised guideline 
was implemented in 2011, on average 10.8% of WBRT pts were 
annually classified as RPA 3. In the year after implementing the 
guideline, this was 7.7 % (p=0,353). Median survival for NSCLC RPA 
class 1, 2, and 3 was 6.5 [95% CI = 3.8-9.2]; 3.0 [95% CI =2.3-3.7] and 
1.5 [95% CI = 0.7-2.2] months, respectively. For SCLC this was 9.0 [95% 
CI = 8.0-10.0]; 4.4 [95% CI = 2.9-6.0] and 2.0 [95% CI = 0.2-3.,8] 
months, respectively (see figure 1). 
 
 Figure1: Overall survival analysis. 
 
Conclusions: Although it is not advised that RPA class 3 pts should 
receive WBRT, approximately 13 % of the analyzed WBRT pts were 
classified as RPA 3. Despite the release/implementation of the new 
national guideline in 2011, we did not find a significant difference 
regarding the treatment of RPA class 3 pts thereafter. The survival of 
RPA class 3 pts is poor and in agreement with RTOG validation studies. 
In our view, guidelines should be implemented more precisely. Better 
awareness amongst physicians would prevent some patients from 
being treated unnecessarily. 
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Purpose/Objective: Standard treatment of locally advanced non-small 
cell lung cancer (NSCLC) corresponds to concomitant chemo-
radiotherapy (2 Gy per fraction until 60-66 Gy). A phase I trial was 
initiated in order to analyse toxicity of standard chemoradiotherapy 
(46 Gy, 2 Gy per fraction) with a stereotactic ablative radiotherapy 
(SABR) boost. The aim of the present study was to develop an 
algorithm able to determine biological equivalent dose received by 
every organ at risk and target volume during radiotherapy using two 
different fractionation schedules. 
Materials and Methods: A phase I trial began in our center in 2010 
and analyzes toxicity after chemoradiotherapy (46 Gy with docetaxel 
and cisplatinum, 2 Gy per fraction) and a boost delivered by SABR (3 X 
7 Gy for the first level, 3 X 12 Gy for the last level). Conventional 
treatment dose matrix and stereotactic dose matrix were fused on the 
same CT-scan (used for SABR treatment). Histogram dose volume was 
evaluated by summation of physical dose after biological conversion 
for each voxel by using the linear quadratic-linear model (LQ-L) and 
the α/β ratio of the delinated organ (ARTIVIEW, AQUILAB SAS, 
France). 
Results: With a median follow-up of 21 months (5-26), 14 patients 
(pts) were treated and 12 (85.7%) experienced grade 1-2 toxicities (no 
grade 3-4 toxicities). One patient died of massive hemoptysis 6 
months after treatment, but also after local and metastatic relapse, 
and bevacizumab treatment. The most frequent toxicity was G1-2 
pulmonary alveolitis (8 pts, 57.1%).When considering dose constraints 
used in conventional treatment, post-hoc analysis of matrix-dose 
revealed that bioequivalent cumulative dose were above the usual 
recommended dose in 3 pts for brachial plexus, 6 pts for pulmonary 
arteries, 4 for superior cave veinous, 2 for heart, 3 for bronchial tree, 
8 for bone, and 3 for lung. When comparing biological summation for 
both conventional and SABR treatment, with only conversion for the 
SABR part there was a median difference of -0.35 Gy (-5.1 ;+0.8). 
Patient with hemoptysis had the highest dose delivered to the big 
vessels (141.7 Gy). 
Conclusions: One toxic death was suspected in this trial and 
correlated with the highest dose received to the big vessels but other 
factors could also explain this event. Otherwise a lot of pts received a 
dose over the limit of dose constraint but with up to now, no grade 3-
5 toxicities suggesting that the LQ-L might not well predict toxicities 
when mixing conventional and SABR treatments, and might 
overestimate bioequivalent dose. This has to be confirmed with longer 
follow-up and a larger number of patients. 
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The last decade has shown a tremendous increase in technological 
developments in radiotherapy in which many types of advanced 
technology emerged. These steps forward concerned: 1) Access of RT 
departments to new diagnostic imaging equipment; 2) Installation of 
new treatment modalities allowing dose delivery that are more 
precise, faster or with greater biological effectiveness; 3) Availability 
of numerous QA devices to verify the dose delivery and patient 
position before or during their treatment; 4) Electronic data transfer. 
Not all potential improvements have led to large scale clinical 
implementation. Cost and reimbursement are obvious reasons, but the 
implementation of new treatment modalities depends also on the 
availability of sufficient expertise and manpower in a department.  
 A large number of physical, technical and clinical problems have to 
be solved before advanced technology can be used in an optimal way. 
For instance, combination of diagnostic imaging information may yield 
improved knowledge of the position of target volume and organs at 
risk, while more advanced optimization and dose calculation 
algorithms may allow better target coverage and sparing of organs at 
risk. However, knowing the possibilities and limitations of these 
procedures is a prerequisite for their safe use by the treatment 
planning team; a process in which medical physicists play an essential 
role. Implementation of new treatment modalities such as proton and 
carbon-ion therapy is still far from routine practice and requires 
